RANI (Rani Therapeutics Holdings) ROE % Adjusted to Book Value: -35.51% (As of Mar. 2026)


RANI Rani Therapeutics Holdings Inc RANI
32 GF Score
Price $0.74
! 3 Warning Signs
View Full Analysis

What is Rani Therapeutics Holdings ROE % Adjusted to Book Value?

Rani Therapeutics Holdings RANI -0.58% 32 ROE % Adjusted to Book Value is -35.51% as of Mar. 2026. GuruFocus rates RANI with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Rani Therapeutics Holdings's ROE % for the quarter that ended in Mar. 2026 was -91.61%. Rani Therapeutics Holdings's PB Ratio for the quarter that ended in Mar. 2026 was 2.58. Rani Therapeutics Holdings's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -35.51%.

Rani Therapeutics Holdings ROE % Adjusted to Book Value Related Terms

Rani Therapeutics Holdings ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Rani Therapeutics Holdings's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rani Therapeutics Holdings ROE % Adjusted to Book Value Chart

Rani Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 0.00 -17.93 -20.33 -17.70 -42.49

Rani Therapeutics Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -82.15 -35.51

RANI vs CGTX, INO, ALDX: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Rani Therapeutics Holdings's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rani Therapeutics Holdings ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Rani Therapeutics Holdings's ROE % Adjusted to Book Value falls into.


RANI
32GF Score
Rani Therapeutics Holdings Inc RANI
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rani Therapeutics Holdings ROE % Adjusted to Book Value Calculation

Rani Therapeutics Holdings's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-169.55% / 3.99
=-42.49%

Rani Therapeutics Holdings's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-91.61% / 2.58
=-35.51%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -35.51% mean?
Rani Therapeutics Holdings (RANI) has a ROE % Adjusted to Book Value of -35.51% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Rani Therapeutics Holdings and its competitors.
Is Rani Therapeutics Holdings' ROE % Adjusted to Book Value too high?
Rani Therapeutics Holdings' current ROE % Adjusted to Book Value is -35.51%. Overall, Rani Therapeutics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Rani Therapeutics Holdings' ROE % Adjusted to Book Value compare to CGTX and INO?
Rani Therapeutics Holdings' ROE % Adjusted to Book Value of -35.51% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Rani Therapeutics Holdings and its competitors. Rani Therapeutics Holdings's current ROE % Adjusted to Book Value is -35.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rani Therapeutics Holdings stock overvalued right now?
Rani Therapeutics Holdings (RANI) has a current ROE % Adjusted to Book Value of -35.51%. The current ROE % Adjusted to Book Value is -35.51%. Rani Therapeutics Holdings' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Rani Therapeutics Holdings (RANI), the current ROE % Adjusted to Book Value is -35.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rani Therapeutics Holdings Business Description

Address 2051 Ringwood Avenue, San Jose, CA, USA, 95131
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
32GF Score

Get the complete analysis for RANI

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.74
Price